The second 600 billion market capitalization pharmaceutical stock appeared!

The first half of 2021 will officially end, and the three major A-share indexes collectively closed up
.

In terms of pharmaceutical stocks, as of the close of business on June 30, 17 pharmaceutical stocks, including Mindray Medical, WuXi AppTec, Hengrui Pharmaceuticals, Pien Tze Huang, and Fosun Pharma, were valued at 100 billion yuan

17 pharmaceutical stocks with a market value of 100 billion leading the way! 3 soaring over 100 billion, the "one brother of Chinese medicine stocks" hit a new high

List of 100 billion market capitalization pharmaceutical stocks

In the first half of 2021, the three major A-share indexes closed up collectively.

Judging from the performance of the first half of the year, it can be described as a twists and turns.
It rose sharply before the Spring Festival, adjusted after the holiday, and continued to rise after bottoming out.

It is worth mentioning that many pharmaceutical stocks have repeatedly set new highs recently.
Mindray Medical has become the second pharmaceutical stock with a market value of 600 billion after Hengrui Pharmaceuticals last year; WuXi AppTec hits a market value of 500 billion; Pien Tze Huang won the "Chinese medicine stocks".
After the throne of "One Brother", we are striding towards the 300 billion mark
.

At the close of the market on July 1, Mindray Medical had a market value of 603 billion yuan, WuXi AppTec's 495.

WuXi AppTec: In May 2018, WuXi AppTec was listed on the A-share market.
One year after its listing, the market value of WuXi AppTec exceeded 150 billion yuan; in 2020, it exceeded the 300 billion mark; as of the first half of 2021, WuXi AppTec's market value exceeded 450 billion yuan.
Surpassed Hengrui Medicine and rose to the second place
.

In recent years, WuXi AppTec's performance has grown rapidly.

Pien Tze Huang: In June 2020, the company's market value exceeded 100 billion yuan.
In September, its market value surpassed Yunnan Baiyao and became the market value leader of the Chinese medicine sector; this year, the market value of Pien Tze Huang has increased by more than 100 billion yuan, surpassing the 270 billion yuan mark
.

Regarding the company’s future development strategy, Pien Tze Huang pointed out in the annual report that the company closely focuses on its main business, takes the brand as the banner and capital as the link, and actively expands to the upstream and downstream of the industrial chain, forming a "one core and two wings" strategic development pattern.

More than 60% of the pharmaceutical stock market value increased! Guangyuyuan, Harbin Sanlian.
.
.
39 doubled

Pharmaceutical stocks that rose more than 100%

In terms of growth and decline, more than 60% of the pharmaceutical stock market has increased in value.

Among them, 39 companies including Guangyuyuan, Harbin Sanlian, Jiaying Pharmaceutical, and Jianmin Group have doubled, and Nanomicro Technology has the largest increase, exceeding 10 times; Common Pharmaceutical All 12 animals, such as, Rejing Biology, etc.
, are more than 300%

On the evening of June 30, Hotview Biotechnology released a performance forecast.

It is expected that the net profit in the first half of 2021 will be 1.
38 billion to 1.
6 billion yuan, a year-on-year increase of 70546.
05% to 81808.

Entering July, the new market value delisting regulations were officially implemented, and stocks with a total market value of less than 300 million yuan for 20 consecutive trading days will be terminated from listing
.

Judging from the market value ranking of pharmaceutical stocks in the first half of the year, the market value of the company closest to the "300 million yuan" red line also exceeded 800 million yuan

List of Pharmaceutical Stock Market Value

Source: Oriental Fortune.
com, Announcement of Listed Companies

Note: If there is any omission, please correct me!